Inmune Stock Valuation

Do you wonder what the value of Inmune Bio is? Calculating the true value of any business is not as easy as it may seem. While the market cap of a public entity, such as Inmune Bio, is its stock price multiplied by the total number of shares outstanding, calculating Inmune Bio's enterprise value requires a different approach. It uses Inmune Bio's balance sheet items such as long-term debt, the book value of the preferred stock, minority interest, and other important financials.
Inmune Bio Enterprise Value is projected to increase significantly based on the last few years of reporting. The past year's Enterprise Value was at 112.06 Million. The current year Tangible Asset Value is expected to grow to about 90 M, whereas Free Cash Flow is forecasted to decline to (29.3 M).
Inmune Bio seems to be undervalued based on Macroaxis valuation methodology. Our model calculates the value of Inmune Bio from evaluating the firm fundamentals such as Return On Equity of (46.96) %, return on asset of (24.25) %, and Shares Owned by Insiders of 35.06 % as well as inspecting its technical indicators and Probability Of Bankruptcy. In general, we encourage taking in undervalued assets and trading overvalued assets since, at some point, asset prices and their ongoing real values will come together.
  
Inmune Bio Valuation Module provides a unique way to ballpark how much the company is worth today. It is done using both, our quantitative analysis of the company fundamentals as well as its intrinsic market price estimation to project the real value. We also take into consideration other essential factors such as Inmune Bio's management style, its c-level domain expertise and tenure, its overall leadership history as well as current capital structure, and future earnings potential.
Traditionally analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Inmune Bio's intrinsic value based on its ongoing forecasts of Inmune Bio's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Inmune Bio's closest peers. When choosing an evaluation method for Inmune Bio, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using both methods to arrive at a better estimate.

Inmune Valuation Drivers Correlation

Many accounts on the financial statements of Inmune Bio are highly interrelated and sometimes correlated. Consequently, when conducting Inmune's valuation analysis, one should examine all of the accounts reported to obtain a complete picture of its financial situation. We provide a unique feature to present a conventional correlation table purposely composed against different valuation-related drivers of Inmune
Click cells to compare fundamentals

Inmune Valuation Trend

Knowing Inmune Bio's actual value is paramount for traders to make sound investment determinations. Inmune Bio's real value is not only important for the investor to make better decisions but also for a more accurate overall view of Inmune Bio's financial worth over time since having this information enables investors and analysts to forecast the earnings more efficiently. Using both Inmune Bio's enterprise value as well as its market capitalization is the best way to gauging the value of the company and is usually enough for investors to make market timing descisions.

Inmune Market Cap

Inmune Bio is currently regarded as number one stock in market capitalization category among related companies. Market capitalization of Biotechnology industry is currently estimated at about 346.52 Million. Inmune Bio totals roughly 173.26 Million in market capitalization claiming about 50% of stocks in Biotechnology industry.
Capitalization  Workforce  Valuation  Revenue  Total debt

Inmune Bio Valuation Ratios as Compared to Competition

Comparative valuation techniques use various fundamental indicators to help in determining Inmune Bio's current stock value. Our valuation model uses many indicators to compare Inmune Bio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Inmune Bio competition to find correlations between indicators driving Inmune Bio's intrinsic value. More Info.
Inmune Bio is currently regarded as number one stock in price to earning category among related companies. It is currently regarded as number one stock in price to sales category among related companies . The current year Price to Sales Ratio is expected to grow to 932.93. Comparative valuation analysis is a catch-all model that can be used if you cannot value Inmune Bio by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Inmune Bio's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Inmune Bio's earnings, one of the primary drivers of an investment's value.
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Inmune Bio's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Inmune Bio and how it compares across the competition.

About Inmune Bio Valuation

The equity valuation mechanism determines the current worth of Inmune Bio on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Inmune Bio. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Inmune Bio based exclusively on its fundamental and basic technical indicators. By analyzing Inmune Bio's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Inmune Bio's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Inmune Bio. We calculate exposure to Inmune Bio's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Inmune Bio's related companies.
Last ReportedProjected for 2022
Gross Profit181 K150.8 K
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patients innate immune system to treat disease. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida. Inmune Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10 people.

Inmune Bio Valuation Growth Rates

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Inmune Bio does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
Quick Ratio22.44
Revenue Growth3,975.00%
Enterprise Value To Revenue322.14

Inmune Bio Current Valuation Indicators

Valuation refers to the process of determining the present value of Inmune Bio and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Inmune we look at many different elements of the entity such as Inmune's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation. Inmune Bio's valuation analysis is also a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Inmune Bio's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Inmune Bio, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Inmune Bio's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Inmune Bio's worth.
Please see Risk vs Return Analysis. Note that the Inmune Bio information on this page should be used as a complementary analysis to other Inmune Bio's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Other Tools for Inmune Stock

When running Inmune Bio price analysis, check to measure Inmune Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inmune Bio is operating at the current time. Most of Inmune Bio's value examination focuses on studying past and present price action to predict the probability of Inmune Bio's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Inmune Bio's price. Additionally, you may evaluate how the addition of Inmune Bio to your portfolios can decrease your overall portfolio volatility.
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go